Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
IMS Health and Reltio have announced that IMS Health is offering Reltio Cloud with its Nexxus™ Commercial Application Suite and IMS One™ platform. Through the alliance, IMS Health will offer life sciences organizations new options for fast, scalable ...
read more
IMS Health and Quintiles have announced that their respective boards of directors approved a definitive merger agreement, pursuant to which the companies will be combined in an all-stock merger of equals transaction.
read more
IMS Health Holdings, Inc. and Quintiles Transnational Holdings Inc. have announced key senior management roles in the future Quintiles IMS corporate leadership team, subject to the completion of the merger.
read more
ImprimisRx has agreed to a product supply agreement with EyeCare Services Partners (ESP).
read more
ImprimisRx has agreed to a product supply agreement with iOR Partners.
read more
Tuesday, December 10, 2019
ImprimisRx announced that on December 9, 2019, its FDA-registered 503B outsourcing facility received a non-resident operating license and has now begun shipping into California.
read more
ImprimisRx has agreed to a product supply agreement with Vision Center Network of America (VCNA).
read more
Imprimis Pharmaceuticals has announced that it has commenced construction on the company's Allen, Texas compounding pharmacy and plans to register the pharmacy with the U.S. Food and Drug Administration (FDA) as a 503B sterile outsourcing facility ...
read more
Imprimis Pharmaceuticals has made available a customizable compounded formulation of pyrimethamine and leucovorin available for physicians to consider prescribing for their patients as a low cost alternative to Daraprim®.
read more
Imprimis Pharmaceuticals has filed for registration of its recently-constructed New Jersey facility with the U.S. Food and Drug Administration (FDA) as a 503B outsourcing facility. The state-of-the-art facility is expected to begin manufacturing as ...
read more
Imprimis Pharmaceuticals, a pharmaceutical company focused on the development and commercialization of proprietary and customizable drug formulations, announced that it has filed for registration of its ImprimisRx TX pharmacy, located in Allen, Texas...
read more
Friday, February 17, 2017
Imprimis Pharmaceuticals has begun shipping its core sterile ophthalmic medications to select customers from its FDA-registered outsourcing facility without the need for a patient-specific prescription. Over the next few weeks Imprimis' flagship ...
read more
Wednesday, January 24, 2018
Imprimis announced its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate.
read more
Wednesday, November 12, 2014
Implandata Ophthalmic Products GmbH (Implandata) an ophthalmic surgical product and e-Health start-up company announces the closing of a €3M Series B-Round. Born2Grow Venture Partners, a private fund based in Heilbronn/Germany joins in as new ...
read more
Wednesday, February 08, 2017
Impel NeuroPharma, a Seattle-based clinical stage biotechnology company developing first-in-class intranasal drug treatments announced has entered into service agreements with Camargo Pharmaceutical Services, LLC ("Camargo").
read more